ESPR
Esperion
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Signals Analysis
Buy signal 3
Sell signal 1
Consensus Rating "Strong Buy"
Significant Net Income Decline
Revenue Beats Expectation
EPS Beats Expectation
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About ESPR
Esperion Therapeutics, Inc.
A late-stage pharmaceutical company that develops therapies to treat low-density lipoprotein cholesteol and other cardiometabolic risk factors
3891 Ranchero Drive, Suite 150, Ann Arbor, Michigan 48108
--
Esperion Therapeutics, Inc., was incorporated in Delaware in January 2008. The Company is a late-stage pharmaceutical company focused on developing and commercializing complementary, convenient, cost-effective once-daily oral therapies for the treatment of patients with elevated LDL-C. Through scientific and clinical excellence and a deep understanding of cholesterol biology, the company's experienced lipid management team is committed to developing new LDL-C lowering therapies that will have a significant impact on reducing global cardiovascular disease or cardiovascular disease; a leading cause of death worldwide.
Company Financials
EPS
ESPR has released its 2025 Q1 earnings. EPS was reported at -0.21, versus the expected -0.15, missing expectations. The chart below visualizes how ESPR has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
ESPR has released its 2025 Q1 earnings report, with revenue of 65.00M, reflecting a YoY change of -52.81%, and net profit of -40.45M, showing a YoY change of -166.30%. The Sankey diagram below clearly presents ESPR's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
